Oncology

The criteria to enroll cancer patients in a clinical trial of CAR-T cells vary according to their disease, past therapy, and how far along they are in different treatments, said David L. Porter, MD, of the University of Pennsylvania Health System.

A multicollaborative study has identified gaps in existing quality measures used by accountable care programs that could result in missed opportunities to improve patient outcomes.

Patient-centered medical homes are valuable because they allow insurers to look at the cost of all of the patient’s treatments, services, and physicians throughout the continuum of care, explained Kim Eason, manager at Horizon Blue Cross Blue Shield of NJ.

The American College of Cardiology is set to hold its annual meeting in the nation's capital March 17-20, 2017.

A retrospective analysis of evidence from prescription data gathered in Belgium and Italy has found that uncontrolled diabetes might be an early sign of pancreatic cancer.

A review of 2013 cancer statistics in the United States by the CDC showed that 67% of people survived at least 5 years after their cancer diagnosis.

Technological advances in cancer care have changed the very process of treatment, as now oncologists can gain more insight into the most effective therapy for each individual patient, according to Joseph Alvarnas, MD, of the City of Hope and editor-in-chief of Evidence-Based Oncology.

This week, the top managed care stories included Aetna and Humana's merger getting blocked, the first Affordable Care Act replacement proposal was unveiled, and an analysis of regional cancer death trends.

Patients who have had at least 1 prior therapy or carry a 17p deletion or TP53 mutation are now eligible to be treated with ibrutinib (Imbruvica) in the United Kingdom.

The most transformative software companies are those that have seized the opportunity to incorporate clinician and patient voices into the design of their health IT tools, according to Carrie Stricker, PhD, RN, AOCN, chief clinical officer and co-founder of Carevive.

The American Journal of Managed Care® presents its annual special issue of Evidence-Based Oncologyâ„¢ featuring full coverage of the 58th annual meeting of the American Society of Hematology. CAR T-cell treatments gained notice, as did sessions on patients’ improving quality of life and addressing the high costs of new therapies.

“Off-the-shelf” chimeric antigen receptor (CAR)-T cells, also known as universal donor cells, were used in 2 young infants with relapsed, refractory acute lymphoblastic leukemia resulted in molecular remission in 28 days in both infants.

Researchers from the Peter O’Donnell Jr. Brain Institute and Harold C. Simmons Comprehensive Cancer Center at the University of Texas Southwestern may have found the ultimate drivers of glioblastoma cell proliferation.

Expansion of Medicaid coverage prior to the authorization of the Affordable Care Act (ACA) in 2010 reduced the uninsured rate in New York State, but did not improve access to cancer surgery.

At the 58th annual meeting of the 58th American Society of Hematology, representatives from 2 national clinical trials, Beat AML and NCI-MATCH, detailed how they were incorporating genomic profiling to assign patients to different treatment arms.

An analysis of cancer death records across the country, by researchers at the University of Washington, has identified clusters of counties that had a particularly high rate of mortality depending on the cancer type.

Researchers implementing the TAPUR trial have encountered some difficulties, particularly in filling the study cohorts, said Pam Mangat, MS, associate director TAPUR study at the American Society of Clinical Oncology (ASCO). However, the ASCO team is dedicated to forging ahead and addressing those challenges.

A system-wide immune response, not just a local response limited to the tumor, is what determines successful remission following cancer immunotherapy.

While one study identified novel mutations and gene amplifications, the other found a wider gap in racial disparity with respect to mortality rates.

Although national guidelines call for men and women at average risk for colorectal cancer (CRC) to begin screening for the disease at age 50, by some estimates, compliance is a mere 38%.

Disease status, MUD/MRD donor, myeloablative conditioning regimen, GVHD prophylaxis other than tacrolimus/sirolimus, and Medicare and/or Medicaid as payer are significant predictors for cost of care in patient with acute leukemia who undergo allogenic hematopoietic cell transplant (AHCT).

Patients diagnosed with diffuse large B-cell lymphoma (DLBCL) who relapsed following first-line treatment had higher rates of healthcare utilization and greater costs than the patients who had not relapsed.

Initiated by the American Board of Internal Medicine, Choosing Wisely® is a campaign that has seen participation by a number of different national medical organizations to promote conversations between clinicians and patients to ensure adequate, evidence-based care.

The Information Exchange and Data Transformation initiative at the FDA uses oncology data from not only clinical trials but also electronic health records and biosensors. This patient-centered approach brings research to the real world, as many oncology patients are excluded from clinical trials, said Sean Khozin, MD, MPH, senior medical officer at the FDA.

The state of current software systems, primarily electronic medical records, is a significant barrier to implementing successful health IT tools, said Jonathan Hirsch, founder and president of Syapse. He also explained some of the solutions developed by Syapse to address these challenges, like improving the software’s integration capabilities and making it more usable for providers.